Maynard Um
-
-
-
-
-
-
-
Freedom Capital Markets Downgrades Amgen (AMGN) to Hold (mid morning)
-
-
-
-
-
-
-
Amgen (AMGN) Tops Q4 EPS by 56c, Beats on Revenue; Offers FY26 Guidance
-
-
-
-
-
-
-
Bernstein SocGen Group Downgrades Amgen (AMGN) to Market Perform
-
-
-
-
-
-
-
Amgen expands direct-pay program, cuts drug prices up to 80%
-
-
-
-
-
-
-
Amgen (AMGN) PT Raised to $372 at BMO Capital
-
-
-
-
-
-
-
Baird Reiterates Underperform Rating on Amgen (AMGN), '3Q25 Financials Look Mostly Solid'
-
-
-
-
-
-
-
AstraZeneca's Tezspire gets FDA approval for nasal polyp condition
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

